Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05680012 · ClinicalTrials.gov registry record · NA
Tissue Destruction and Healing in Celiac Disease
A NA study of Celiac Disease, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 220
- Enrollment target
- 3
- Study locations
NCT05680012: Recruiting NA study of Celiac Disease, sponsored by University of Chicago.
NCT05680012 is a NA study of Celiac Disease that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 220 participants, below the 1,971-participant average among 24 other Celiac Disease trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05680012, a NA study of Celiac Disease, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate better resources to advance celiac disease patient care.
Primary Outcome
villus to crypt ratios will be quantified on small bowel biopsy samples for the histologic quantification of intestinal responses to disease processes.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Gluten containing snack bar
Study Locations (3)
California
- California Institute of Technology - Pasadena
Illinois
- The University of Chicago - Chicago
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2023-07-14 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT05680012 shows while recruiting
NCT05680012 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 1,971-participant average among 24 other Celiac Disease trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Celiac Disease appearing as the primary indexed condition, and to 1 intervention - of which Gluten containing snack bar is the first listed.
NCT05680012 reports a single indexed study location in California, Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05680012 about?
NCT05680012 is a clinical study titled "Tissue Destruction and Healing in Celiac Disease". The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on ce...
What is the current status of trial NCT05680012?
This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2023-07-14. Estimated completion is 2027-06-30.
What conditions does trial NCT05680012 study?
This clinical trial studies the following conditions: Celiac Disease.
What interventions are being tested in trial NCT05680012?
The interventions under investigation include: Gluten containing snack bar (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05680012?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05680012 being conducted?
This trial has 3 study locations across California, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Celiac Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05680012's enrollment target sits among peer trials
220 9th of 24 higher than 16 of 24 other Celiac Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Celiac Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immune Responses to Gluten
RECRUITING · NA
-
Gluten Technology and Education for Celiac Health
RECRUITING · NA
-
T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge
COMPLETED · NA
-
Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System
COMPLETED · NA
-
Changes in Intestinal Permeability 4 Hours After Gluten Challenge
COMPLETED · NA
-
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI